Plain-English translation of NCT07437079 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 study testing a new investigational medication called designed to help with weight management. Researchers want to understand how safe this medication is and how the body processes it when given to healthy adults who are overweight or have obesity. This is the first time the medication is being tested in humans.
Obesity and overweight affect millions of people worldwide, and current treatment options are limited. This study is exploring whether this new treatment could become a safe option for people seeking help managing their weight.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic multiple times and receive either the new medication or a placebo (a dummy pill that looks identical) decided by chance. Researchers would then monitor your safety with blood tests, physical exams, and heart monitoring to see how your body responds. The study involves both single doses and repeated doses of the medication over time to understand its safety and how the body processes it.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Novo Nordisk A/S
Enrollment target
~132 participants
Started
February 2026
Primary completion
January 2027
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Novo Nordisk
Novo Nordisk A/S
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.